Rationale and Design of RNAFH Study: Effect of Rosuvastatin (10 mg/d) on Nonalcoholic Fatty Liver in Metabolic Syndrome Patients without Overt Diabetes Evaluated by <sup>1</sup>H-Magnetic Resonance Spectroscopy

<div>Flowchart showing the timetable of the RNAFH study. The total follow-up duration is 52 weeks. <sup>1</sup>H-MRS will be performed at baseline and 52th week. Physical examination, lipid parameters, HOMA-IR, and safety indices including liver function, CK, renal function, and HbA1c will be measured at baseline, 4th, 16th, 28th, and 40th week, and 52nd week.</div>

International Journal of Endocrinology

fig1

Figure 1

Figure 1: Rationale and Design of RNAFH Study: Effect of Rosuvastatin (10 mg/d) on Nonalcoholic Fatty Liver in Metabolic Syndrome Patients without Overt Diabetes Evaluated by <sup>1</sup>H-Magnetic Resonance Spectroscopy 

Figure 1 | Rationale and Design of RNAFH Study: Effect of Rosuvastatin (10 mg/d) on Nonalcoholic Fatty Liver in Metabolic Syndrome Patients without Overt Diabetes Evaluated by 1H-Magnetic Resonance Spectroscopy 